Compare INNV & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INNV | ORIC |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2021 | 2020 |
| Metric | INNV | ORIC |
|---|---|---|
| Price | $7.72 | $10.83 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | $7.00 | ★ $20.00 |
| AVG Volume (30 Days) | 337.0K | ★ 1.4M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $853,699,000.00 | N/A |
| Revenue This Year | $12.85 | N/A |
| Revenue Next Year | $8.88 | N/A |
| P/E Ratio | $59.68 | ★ N/A |
| Revenue Growth | ★ 11.76 | N/A |
| 52 Week Low | $2.60 | $3.90 |
| 52 Week High | $10.69 | $14.93 |
| Indicator | INNV | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 42.46 | 41.27 |
| Support Level | $5.01 | $9.88 |
| Resistance Level | $9.18 | $12.12 |
| Average True Range (ATR) | 0.63 | 0.82 |
| MACD | -0.22 | -0.31 |
| Stochastic Oscillator | 1.00 | 6.87 |
InnovAge Holding Corp is a healthcare delivery platform comprising multiple participants focused on providing all-inclusive, capitated care to high-cost seniors, many of whom are dual-eligible. Its programs are designed to address two of the pressing challenges facing the U.S. healthcare industry: rising costs and poor outcomes. The purpose of the participant-centered care delivery approach is to improve the quality of care participants receive, while keeping them in their homes for as long as possible and reducing the overutilization of high-cost care settings, such as hospitals and nursing homes. The company manages its business as one reportable segment, PACE.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.